Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 51

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 51
---
 factors related to entering into the Merger, including:

| ● | the                              
 Potential Conflicts of Interest; |

| ● | the                                                                                             
 potential expenses to be incurred in connection with the Merger, including the costs associated 
 with any related litigation;                                                                    |

| ● | the                                                                                   
 likelihood of disruptive stockholder litigation following announcement of the Merger; |

| ● | the                                                                                        
 possible volatility, at least in the short term, of the trading price of MIRA Common Stock 
 resulting from the announcement of the Merger;                                             |

| ● | the                                                                                          
 risk that the Merger might not be consummated in a timely manner or at all and the potential 
 adverse effect of the public announcement of the Merger or delay or failure to complete the  
 Merger on the reputation of MIRA;                                                            |

| ● | the                                                                                       
 likely detrimental effect on MIRA’s cash position, stock price and ability to initiate    
 another process and to successfully complete an alternative transaction should the Merger 
 not be completed;                                                                         |

| ● | the                                                                                        
 risk to MIRA’s business, operations and financial results in the event that the Merger     
 is not consummated, including the diminution of MIRA’s cash and the significant challenges 
 associated with the need to raise additional capital through the public or private sale of 
 equity securities;                                                                         |

| ● | the                                                                                      
 risk that the combined company could be subject to the Investment Company Act Rule 3-a2; 
 and                                                                                      |

| ● | various                                                                                    
 other risks associated with the combined company and the Merger, including those described 
 in the section titled “Risk Factors.”                                                      |

Neither MIRA nor the Board considered other merger candidates. MIRA’s CEO was previously familiar with SKNY and its prospects for growth and was interested in acquiring this specific company to increase shareholder value.

In view of the wide variety of reasons considered in connection with its evaluation of the Merger and the complexity of these matters, the MIRA Board did not find it useful to attempt, and did not attempt, to quantify, rank or otherwise assign relative weights to these reasons. In considering the reasons described above, individual members of the MIRA Board may have given different weight to different reasons. The MIRA Board conducted an overall analysis of the factors described above, including thorough discussions with, and questioning of, MIRA’s CEO and the legal and financial advisors of MIRA, and considered the reasons overall to be favorable to, and to support, its determination.

The LOI